The worldwide xerostomia (dry mouth) therapeutics market is projected to reach a valuation of USD 796.1 million by 2025, according to Grand View Research, Inc. Xerostomia is a symptom of Sjögren’s syndrome and radiation-induced chemotherapy. It is putatively known as cottonmouth and doughmouth. The absence of saliva due to the after-effect of various medicines can also cause cottonmouth. According to the San Antonio School of Dentistry, nearly 4 million suffer from Sjögren’s syndrome, an autoimmune disease, in the United States. Pharamceutical manufacturers are focused on launching medicines to treat the symptom.
Dentifrices, salivary substitutes, and salivary stimulants are products used in treating dry mouth and prevent caries as well. For instance, the Biotène range of products by GlaxoSmithKline entails toothpastes, mouthwash, and gel. These can restore saliva flow and prevent caries. Another prominent company, Ortek Therapeutics, has launched soft chews (‘BasicBites’) to maintain enamel and prevent bacterial growth. Saliva substitutes available in the form of sprays or gels can stimulate artificial saliva and prevent tooth decay.
According to the World Health Organization, nearly 8.8 million died from cancer in 2015. The radiation therapy used in treating cancer causes dry mouth, making it difficult to swallow food. According to a study by NRG Oncology in 2016, intensity-modulated radiotherapy (IMRT) with three-dimensional conformal radiotherapy (3D-CRT) had culminated in reduced xerostomia incidence in patients. Parasympathomimetic drugs such as pilocarpine were shown to display similar results with reduced dryness levels of eyes and mouth. Xylitol has also shown success in clinical trials in treating dry mouth induced from radiation.
The xerostomia (dry mouth) therapeutics market is expected to exhibit a 3.2% CAGR from 2017 to 2025. Increasing awareness regarding the symptom and reimbursement policies covering the purchase of medicines for treatment of dry mouth are factors anticipated to drive market growth over the forecast period (2014-2025). Non-availability of treatments in developing economies may hamper market growth. Prominent players in the market include Hikma Pharmaceuticals LLC, GlaxoSmithKline plc, Acacia Pharma, and The Colgate-Palmolive Company.
No comments:
Post a Comment